Lotus Pharmaceutical to Commercialize Formycon's Keytruda® Biosimilar in Asia-Pacific

Lotus Pharmaceutical has secured an exclusive license agreement with Formycon AG to commercialize the biosimilar candidate FYB206, a version of Keytruda® (Pembrolizumab), across major parts of the Asia-Pacific region. This biosimilar aims to expand patient access to effective oncology treatments. Formycon will receive an upfront payment, additional milestone-based payments, and a share of gross profits upon the product's market launch.

FYB206 is nearing the completion of its clinical development phase, with key endpoint data expected by early 2026. Formycon and Lotus will coordinate regulatory preparations tailored to the requirements of the APAC countries. The agreement reflects both companies' commitment to providing more accessible biologic therapies and enhancing their presence in the specialty oncology market.